Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623092 | 0.90 | C5AR1 (0.51) | HTR6KEAP1HTR3EHTR3BCYP1A2 | |
| SCHEMBL1374538 | 0.80 | HTR6 (0.50) | HTR6HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL1380036 | 0.76 | HTR6 (0.56) | HTR6HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL1380665 | 0.74 | HTR6 (0.52) | HTR6KEAP1HTR1AHTR1DHTR1B | |
| SCHEMBL1380282 | 0.74 | HTR6 (0.56) | HTR6HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL1377664 | 0.71 | HTR6 (0.53) | HTR6HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL1378251 | 0.70 | HTR6 (0.52) | HTR6HTR3EHTR3BCYP1A2HTR1A | |
| SCHEMBL12843103 | 0.70 | HTR6 (0.49) | HTR6HTR1AHTR2AHTR7 | |
| SCHEMBL3623679 | 0.70 | KMT2A (0.48) | KEAP1TSHRLMNANFE2L2BACE1 | |
| Hydrochloric Acid SCHEMBL5550104 | 0.69 | KMT2A (0.47) | KEAP1TSHRLMNANFE2L2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4731114-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | claimed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HTR6 1659/4885KEAP1 1645/4885HTR3E 3800/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR6 1213/4885KEAP1 1144/4885HTR3E 3518/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | HTR6 2369/4885KEAP1 309/4885HTR3E 3424/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR6 1213/4885KEAP1 1144/4885HTR3E 3518/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | HTR6 1659/4885KEAP1 1645/4885HTR3E 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.